Pfizer, Teva reach deal to allow generic Viagra

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Pfizer says Teva will pay an undisclosed royalty for a license to produce a of Viagra, one of New York-based Pfizer's best-selling drugs. Viagra generated about $1.14 billion in U.S. sales last year.

Pfizer's patent protecting Viagra from generic competition expires in April 2020, but Teva will be allowed to launch its generic version Dec. 11, 2017.

Pfizer Inc. had sued Teva in 2010 over the Israeli drugmaker's plans to introduce a generic version of Viagra.

The patent protecting another , Eli Lilly and Co.'s Cialis, also expires in 2017.


Explore further

Canada high court voids Pfizer's Viagra patent

© 2013 The Associated Press. All rights reserved.

Citation: Pfizer, Teva reach deal to allow generic Viagra (2013, December 17) retrieved 23 October 2019 from https://medicalxpress.com/news/2013-12-pfizer-teva-viagra.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more